NANCY-STRASBOURG, France –StemInov, a biotechnology company developing an innovative biomedicine based on stem cells from umbilical cords to treat inflammatory diseases, septic shock and acute respiratory distress syndrome (ARDS), will bioproduct the first cell therapy drug from umbilical cord stem. In this context, StemInov’s promising disruptive innovations has been selected to join the French Tech – Health20 program launched by the French Government that will accelerate the development of StemInov’s proprietary and collaborative programs with greater visibility in France and internationally. [Read more…]
Gene & cell therapy manufacturing specialist Ascend launches with over $130M of funding as expert teams merge
LONDON, May 9, 2023 — Ascend Gene & Cell Therapies (Ascend), a specialist company innovating manufacturing processes to improve quality, potency, safety and cost enabling better reach for gene therapy technologies, announces that it has launched as a facilitator for gene therapy companies to help translate product ideas into viable clinical programs.
Ascend offers process development, clinical manufacturing, and analytical and regulatory support for biotech companies working in advanced modalities requiring flexible CMC services. Originally founded by Monograph Capital, Ascend has raised a total of $132.5M, most recently completing a Series A fundraise led by Abingworth and Petrichor, supported by DCVC Bio, 4BIO Capital, Cathay Health, Deerfield Management, Digitalis Ventures and Ajinomoto Co., Inc. [Read more…]
denovoMATRIX launches high potency stem cell products
DRESDEN, Germany, May. 31, 2023 — denovoMATRIX GmbH, an innovator in cell and gene therapy manufacturing, unveiled the broadening of its product portfolio with the launch of its first stem cell product at the annual meeting of the International Society for Cell & Gene Therapy (ISCT) in Paris, France. [Read more…]
convEyXO and SomesTech Announce XomeXBio Joint Venture to Unleash Full Potential of Targeted Exosomes as drug delivery system for precision medicine
The collaboration includes the development, commercialization and supply of a breakthrough platform based on SomesTech nanoengineering technology strengthened and validated by convEyXO to enable loading of exosomes capable to delivering bioactive compounds in a targeted way.
Ronawk Announces the Launch of STELLα: A Groundbreaking Non-Clinical Contract Research Organization (CRO)
Overland Park, KS – Ronawk, a leading biotechnology company, proudly announces the launch of STELLα, a state-of-the-art non-clinical contract research organization (CRO) dedicated to driving innovation in the life sciences industry. The addition of STELLα to Ronawk’s portfolio represents a significant milestone in the company’s growth and expansion, further solidifying its position as a strategic contributor to the region’s growing biotech ecosystem. [Read more…]
- « Previous Page
- 1
- …
- 40
- 41
- 42
- 43
- 44
- …
- 117
- Next Page »